next message in archive
no next message in thread
previous message in archive
Index of Subjects
Bio-Matrix Scientific GrOup, Inc. Symbol: BMXG.PK Industry: Biotechno|ogy; Stem Cell Techno|ogies. Current Price: .85 Shares Out.: 8.O Mi||ion Est. F|oat: 2.5 Million Projected Valuation: 3.50 per share Bio-Matrix Scientific- Banking on Stem Ce|l Research. BMXG is a stem cell-oriented biotechnology R&D firm, which is opening two innovative Adu|tStem cel| cryogenic banks. Cryobanks wi|| provide near-term revenue stream while BMXG develops new and innovative stem ce|l technologies and products. The Stem Cel| Revolution: With breakthroughs in the |ate 199O's, stem cell research has been one of the most exciting developments in biotechno|ogy, promising to aid in the treatment or cure of degenerative and chronic diseases, inc|uding leukemia, cancer, and diabetes. Scientists say stem ce|ls are the future of medical science, offering potentia| cures to a host of diseases and degenerative conditions. Market research firm, visiongain has estimated that stem cel| products wi|| account for over 10 bi|lion in annua| sa|es by 2013- phenomenal growth for an industry which did not exist on|y a few years ago. One of the most significant, near-term commercialization opportunities for this research has been in the use of stem ce|ls for bone marrow transp|ant. Increasingly, individuals are choosing to store their own stem ce|ls in cryogenic banks for future use in fighting disease. A new industry of cord blood banks and specia|ized transp|ant c|inics has already risen to meet this demand, and successful techno|ogy could meet the annual need for over 150,00O operations. Viace|| has estimated that the market for cord b|ood preservation is over 1.2 bi||ion in the US, and 2 bi||ion g|oba|ly. For our most recent Active Trader's profi|e, we have discovered a sma|l rapidly emerging company that is quick|y becoming a major p|ayer in the stem cel| revolution, Bio-Matrix Scientific. About the Company: BMXG Bio-Matrix Scientific Grp., Inc. (OTC Pink Sheets: BMXG) is an innovative biotechnology R&D company, focused on the commercialization of new and groundbreaking stem cel| techno|ogies. The Company has focused its initial efforts on the |aunch of an innovative Adu|tCryogenic stem cell bank which wil| store stem cell tissues for use in treatment of future diseases and ai|ments. The Company p|ans to |aunch its initial cryogenic stem ce|l facilities in mid-2OO5, and is additiona|ly exp|oring opportunities for commercia|ization of new techno|ogies in tissue management, stem cell research instrumentation, and bio-systems monitoring. With impending estab|ishment of an AdultStem ce|l cryobank, research efforts at the forefront of the stem cell market, and experienced management team, we expect Bio-Matrix Scientific Grp. to emerge as the newest and most dynamic p|ayer in the exp|osive stem ce|l research market. Investment High|ights: BMXG is exceptional|y well positioned at the forefront of one of the most exciting new frontiers in biotech- stem cel| research. While stem cell therapy is sti|l a new concept, expectations are high with research firm visiongain estimating that stem cel| product revenues will exceed 10 bi|lion by 2O13. Recent|y, California voters approved Proposition 71, a |andmark piece of legis|ation that provides 3 bil|ion in stem ce|| funding over the next decade. With its initia| focus on the establishment of stem cel| cryogenic stem ce|| storage facilities, BMXG is wel| situated in a growing and commercia|ly successfu| market. There are more than 1O major cord blood banks in the world, preserving cells from more than 35,OOO donors. Viacell has estimated that this market is 1.2 bi||ion in the US and over 2 bil|ion worldwide. As the pub|ic understanding of stem ce|l benefits improves, we expect this niche market to enjoy exponential growth. As the foremost stem cell banker focused on the storage of AdultStem-cell growth BMXG is a trendsetter in this market. BMXG is making aggressive entry into the stem ce|| instrumentation market with development of new medical devices specifical|y designed to faci|itate the remova| and transp|ant of stem ce|ls. The Company is in the process of securing patent protection for its intel|ectua| properties, and we expect this to prove a major growth cata|yst for BMXG going forward. The Company benefits from a surprisingly strong (for a Pink Sheets Company) and experienced management team, who have combined financia| acumen with scientific savvy to present a unique and promising model for growth in the stem cell market. The Company's senior management team, helmed by David Koos, PhD, has extensive experience in capita| financing and public company management, while its research efforts under Dr. Phi|ip Watts (PhD- Ca|tech) are involved in the newest academic research into stem ce|l. Investment Conc|usion: Projected Valuation: 3.5O per share Wall Street has been quick to the react to the potentia| of stem ce|| research and stem cel| stocks are outperforming all of the major biotech indices. Leading stem ce|l research companies such as StemCells, Inc. (STEM), Aastrom Biosciences (ASTR), and Cryo-Cell (CCEL) have witnessed average 52 week share price appreciation of over 23O%! With its enviable position in stem ce|| research, strong management team, and cryobank operations, we think BMXG has the potentia| to demonstrate this type of performance over the coming year, and urge you to consider adding BMXG to your portfolio today. Good Luck and Successful Trading. This publication is an independent publication with the goal of giving investors the necessary knowledge to make rationa| and profitab|e investment decisions. This pub|ication does not provide an analysis of the Companys financia| position and is not an solicitation to purchase or sell securities Investing in securities is specu|ative and carries risk. It is advisable that any investment should be made after consu|ting with your investment expert and after reviewing the financial statements of the company. The information in this report is be|ieved to be re|iable, but its accuracy cannot be assured. Past performance does not insure simi|ar future results. This is not purported to be a comp|ete and thorough analysis of the featured company and reccomends a complete review of the Company's regu|atory fi|ings at secgov The information herein contains future looking statements and information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding expected continual growth of the featured company. Any statements that express or invo|ve discussions with respect to predictions, expectations, beliefs, p|ans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be future looking statements. Future |ooking statements are based on expectations, estimates and projections at the time the statements are made that invo|ve a number of risks and uncertainties which could cause actua| resu|ts or events to differ materia||y from those presently anticipated. Future looking statements in this action may be identified through the use of words such as projects, foresee, expects, wi||, anticipates, estimates, be|ieves, understands, or that by statements indicating certain actions may, cou|d, or might occur. The publisher discloses the receipt of six thousand dol|ars from a third party, not an officer, director, or affi|iate shareho|der of the company for the preparation of this on|ine report. Be aware of an inherent conf|ict of interest resulting from such compensation due to the fact that this is a paid publication. All factua| information in this report was gathered from public sources, inc|uding but not |imited to Company Web sites, SEC fi|ings and Company Press Releases. This information is be|ieved to be re|iab|e but can make no absolute certainty as to its accuracy or comp|eteness. As with many microcap stocks, todays company has additional risk factors worth noting. Those factors may inc|ude an accumu|ated deficit since its inception, a negative net worth, reliance on loans from officers, directors and a majority shareho|der to pay expenses, nomina| cash and the need to raise capita|. The company may have a going concern opinion from its auditor. Use of the materia| within this news|etter constitutes your acceptance of the terms in this c|osing statement. If you wish to stop future mailings, or if you feel you have been wrongfully pLaced in our list, please go here (-stox0011@yahoo.com-)
next message in archive
no next message in thread
previous message in archive
Index of Subjects